Compare D R Horton Inc (DHI) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Davita Inc — how do they compare? D R Horton Inc trades at $135.82 (market cap $37.28B), while Davita Inc trades at $175.04 (market cap $11.28B). The key difference: D R Horton Inc is far larger — about 3.3× Davita Inc's market cap, and D R Horton Inc pays a 1.35% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Davita Inc for 113 Days on average.
| DHI | DVA | |
|---|---|---|
Market Cap | $37.28B | $11.28B |
Volume | 3,571,611 | 650,294 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $240.96 |
52-Week Low | $132.53 | $103.87 |
Typical Hold Time | 46 Days | 113 Days |
Enterprise Value | $42.38B | $24.00B |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $135.82, down 0.68% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with oversold RSI readings, while fundamentals remain solid with consistent earnings beats and attractive valuation at 12.71 P/E. Recent news highlights sector-wide challenges as mortgage rates approach 7%, though the company maintains strong cash flow generation and dividend payments.
Despite near-term headwinds from rising rates, DHI's strong market position, consistent execution, and discounted valuation present opportunity for long-term investors. Key risks include prolonged housing market weakness and further rate hikes, but analyst consensus remains positive with $156.57 price target suggesting 15% upside potential from current levels.
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
